Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature

Charles F. Craddock*, Aimee E. Houlton, Lynn Swun Quek, Paul Ferguson, Emma Gbandi, Corran Roberts, Marlen Metzner, Natalia Garcia-Martin, Alison Kennedy, Angela Hamblin, Manoj Raghavan, Sandeep Nagra, Louise Dudley, Keith Wheatley, Mary Frances McMullin, Srinivas P. Pillai, Richard J. Kelly, Shamyla Siddique, Michael Dennis, Jamie D. CavenaghParesh Vyas

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

71 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature'. Together they form a unique fingerprint.

Medicine and Dentistry

Neuroscience

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology